After the Bell: Amylyx Prices a $471.7M Offering, Nexalin's Small Registered Direct, and Oxford Square's Annual Meeting Results

Five Form 8-K filings landed within about two and a half minutes of each other after the closing bell on August 20, 2026, spanning capital raises, a board addition, an investor presentation, and annual meeting vote results.

Amylyx Pharmaceuticals: underwriting agreement for a stock offering

Amylyx Pharmaceuticals disclosed under Item 1.01 (Entry into a Material Definitive Agreement) that on August 19, 2026 it signed an underwriting agreement with Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC as representatives of the underwriters.

The filing states Amylyx intends to use the proceeds, together with existing cash and marketable securities, to fund a potential commercial launch of avexitide in the United States if approved, including manufacturing capacity, plus research and development and general corporate purposes. Item 1.01 covers agreements a company enters into that are significant enough to require disclosure, here, the contract governing the stock sale itself.

Nexalin Technology: registered direct offering plus warrants

Nexalin Technology also filed under Item 1.01, along with Item 3.02 (Unregistered Sales of Equity Securities), which applies when a company sells securities without registering them under the Securities Act. Here, that covers the warrants sold alongside the registered shares.

The purchase agreement was signed August 19, 2026 with a single institutional investor. The warrants may be exercised on a cashless basis if no effective registration statement or prospectus is available at the time of exercise.

Tredegar Corporation: new independent director

Tredegar’s filing covered Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers), the item used whenever a company’s board or executive lineup changes. On August 17, 2026, Tredegar’s board elected Ana Dutra as a director and as a member of the Executive Compensation Committee, effective immediately. The board determined she qualifies as independent under the company’s standards and NYSE rules, and the filing states there are no arrangements between Dutra and any other person related to her election, and no Item 404(a) reportable transactions between her and the company. She will be compensated under Tredegar’s existing non-employee director program.

The company also checked Item 7.01 (Regulation FD Disclosure), noting it issued a press release on August 20, 2026 about the election, attached as an exhibit. Item 7.01 is used for information a company wants to share broadly and simultaneously with the market, often to comply with fair-disclosure rules; information furnished this way is explicitly not treated as “filed” for liability purposes under the Exchange Act.

First Business Financial Services: investor presentation

First Business Financial Services filed under Item 7.01, disclosing that on August 20, 2026 it posted an investor presentation to its website covering recent operating performance, financial condition, and business strategy. The filing states the company plans to use the presentation when its executives interact with shareholders, analysts, and other third parties. As with Tredegar’s Item 7.01 disclosure, this information is furnished rather than filed.

Oxford Square Capital Corp.: annual meeting results

Oxford Square Capital filed under Item 5.07 (Submission of Matters to a Vote of Security Holders), which covers the results of shareholder votes at a meeting. The Annual Meeting was held August 20, 2026, with a record date of June 30, 2026 and 105,058,242 shares entitled to vote.

Both director nominees will serve three-year terms expiring at the 2029 Annual Meeting, and Ernst & Young LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026.

Sourced directly from Form 8-K filings on SEC EDGAR. Not investment advice; see About for what this site does and doesn’t do.